Table 31Relative risks from single covariate meta-regressions—overall survival: epoetin or darbepoetin versus control

CharacteristicGroupRR (95% CI)p-value
Dose EscalationYes1.00 (0.95 to 1.05)0.98
No0.99 (0.90 to 1.09)
IronAll other0.96 (0.89 to 1.03)0.07
As necessary1.04 (0.93 to 1.17)
Platinum-Base ChemotherapyYes1.05 (0.98 to 1.13)0.12
No0.98 (0.87 to 1.10)
Chemo or RadiotherapyChemo ± Radiotherapy1.00 (0.95 to 1.05)0.19
Radiotherapy1.09 (0.94 to 1.25)
Baseline Hb b> 10 g/dL0.97 (0.88 to 1.07)0.30
≤ 10 g/dL1.03 (0.89 to 1.20)
Study Duration≤ 12 weeks0.97 (0.83 to 1.13)0.67
> 12 weeks1.00 (0.83 to 1.20)
Study QualityLow1.00 (0.94 to 1.07)0.71
High1.02 (0.90 to 1.14)
BlindingYes1.02 (0.95 to 1.09)0.71
No1.00 (0.89 to 1.13)

CI = confidence interval; RR = relative risk

From: Results

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.